Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients
- 1 March 1997
- journal article
- Published by Elsevier in Psychiatry Research
- Vol. 69 (2-3) , 105-111
- https://doi.org/10.1016/s0165-1781(96)02999-x
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia: With particular reference to drug resistanceSchizophrenia Research, 1993
- Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?Psychopharmacology, 1992
- Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patientsPsychiatry Research, 1991
- Haloperidol kinetics and clinical responseSchizophrenia Research, 1991
- Metabolites of haloperidol display preferential activity at σ receptors compared to dopamine D-2 receptorsEuropean Journal of Pharmacology, 1990
- Pharmacokinetics of HaloperidolClinical Pharmacokinetics, 1989
- Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patientsBiological Psychiatry, 1989
- Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysisClinical Pharmacology & Therapeutics, 1989
- Extrapyramidal reactions in AsiansAmerican Journal of Psychiatry, 1981
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980